

Pathologic Stage III Cutaneous Melanoma AJCC v8

National Cancer Institute

Source

National Cancer Institute. *Pathologic Stage III Cutaneous Melanoma AJCC v8*. NCI Thesaurus. Code C137670.

Stage III includes: IIIA: (T 1a/b-T2a, N1a or N2a, M0); IIIB: (T0, N1b, N1c, M0); (T 1a/b-T2a, N1b/c or N2b, M0); (T 2b/T3a, N1a-N2b, M0); IIIC: (T0, N2b, N2c, N3b or N3c); (T 1a-T3a, N2c or N3a/b/c, M0); (T 3b/T4a, Any N greater than or equal to N1, M0); (T 4b, N1a-N2c, M0); IIID: (T 4b, N3a/b/c, M0). T 1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T 1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T 2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. T 0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T 2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T 3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T 3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T 4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T 4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration. N 1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N 2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N 1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N 1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N 2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N 2c: One clinically occult nodal metastasis. Presence of in-transit, satellite, and/or microsatellite

metastases: Yes. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)